Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 6671-6680 of 11276

Edit search filters
  1. Trial of TRC105 and Sorafenib in Patients With HCC

  2. Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD)

    Scottsdale/Phoenix, AZ

  3. Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)

    Rochester, MN, Jacksonville, FL

  4. MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

    Rochester, MN

  5. A Study of Intrathecal SHP611 in Participants With Late Infantile Metachromatic Leukodystrophy

    Rochester, MN

  6. Trial Of The F2 Filter And Delivery System For Embolic Protection During TAVR

    Rochester, MN

  7. InSpace Accelerated Rehabilitation Study (iAccelerate)

    Rochester, MN

  8. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

    Jacksonville, FL, Rochester, MN

  9. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL

    Rochester, MN

  10. A Study Comparing Sublobar Resection versus Stereotactic Ablative Radiotherapy for Lung Cancer

    Rochester, MN

.

Mayo Clinic Footer